Another treatment option for relapsed or refractory chronic lymphocytic leukaemia
Mené sur 416 patients atteints d'une leucémie lymphoïde chronique réfractaire ou récidivante, cet essai de phase III évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité de l'ajout de l'idélalisib, un antagoniste de l'isoforme delta
Most patients with chronic lymphocytic leukaemia relapse after front-line chemoimmunotherapy and a substantial proportion develop adverse genetic abnormalities leading to disease that is refractory to treatment. The introduction of targeted agents, such as the kinase inhibitors ibrutinib and idelalisib and the BCL2 antagonist venetoclax, has substantially improved the outcomes of patients with relapsed or refractory chronic lymphocytic leukaemia.1–3 These agents induce durable responses in patients with standard as well as high-risk disease features
The Lancet Oncology , commentaire, 2016